Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 11 2022 - 8:00AM
Business Wire
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical
company focused on the development, production, sale, and
distribution of innovative ophthalmic prescription medicines, today
announced that Mark L. Baum, Chief Executive Officer, and Andrew
Boll, Chief Financial Officer, will participate in the H.C.
Wainwright 2nd Annual Ophthalmology Virtual Conference to be held
on August 17, 2022.
Harrow Health’s pre-recorded presentation will be available via
a link on the investor relations section of its website,
harrowinc.com, beginning at 7:00 a.m. ET on Wednesday, August 17,
2022, and will remain archived there for approximately 90 days.
Harrow Health’s management team will be participating in one-on-one
meetings during the conference. Interested investors can request
meetings exclusively via H. C. Wainwright.
About Harrow Health
Harrow Health, Inc. (Nasdaq: HROW) is an eyecare pharmaceutical
company focused on the development, production, sale, and
distribution of innovative ophthalmic prescription medications that
are accessible and affordable. For more information about Harrow
Health, please visit the Investors section of the corporate
website, harrowinc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220811005152/en/
Jamie Webb Director of Communications and Investor Relations
jwebb@harrowinc.com 615-733-4737
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2023 to Apr 2024